Catalent stays hot as it inks deal with French pharma that suffered PhIII flop
Just a couple of deals in a couple of days for Catalent.
The New Jersey-based CDMO’s latest move is a long-term supply agreement with Erytech Pharma, a French clinical-stage biopharma, and the purchase of its cell therapy manufacturing site in the motherland.
The deal is good for $44.5 million, and 40 of Erytech’s Princeton, NJ employees will be offered employment by the site’s new owner. Catalent will now make Erytech’s lead candidate Graspa for clinical and commercial supply in the US. Graspa is in Phase I trials in patients suffering from pancreatic cancer right now and is in talks with the FDA for a BLA submission in hypersensitive ALL. That’s targeted in Q3 2022.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.